EC clears sale of Altana Pharma to Nycomed
The European Commission has cleared, under the European Union merger regulation, the proposed $5.7 billion acquisition of Altana Pharma of Germany by Nycomed of Denmark (Marketletter October 2). The Commission concluded that the operation would not significantly impede effective competition in the European Economic Area or any substantial part of it.
Nycomed manufactures and markets hospital products throughout Europe, and prescription and over-the-counter medicines in various European countries. It is jointly controlled by Nordic Capital Fund V (Jersey) and Credit Suisse Group (Switzerland).
Altana researches, develops, manufactures and sells pharmaceuticals with a focus on innovative medicines for gastrointestinal and respiratory diseases, self-medication products and medical imaging. Altana is mainly active in Europe and in South America.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze